Table 12. References for studies on non-cisplatin chemoradiotherapy regimen (continued).
| Study, author | Arms | Severe acute toxicity (grade 3–5) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pts (no.) | N/V | Mucositis | Dysphagia | Leukopenia | Neutropenia | Tbcp | Anemia | Infection | Renal | Neuro | Skin | Ototoxic | Total toxic deaths | All | Diff in acute toxicity | ||
| Bonner et al. (19) | A. RT alone | 212 | 6% | 52% | 30% | – | – | – | 6% | 1% | – | – | 1% | – | – | – | No sig diff |
| B. Cetux-CRT | 208 | 4% | 56% | 26% | – | – | – | 1% | 1% | – | – | 17% | – | – | – | ||
| Gillison et al. (20) | A. HDC-CRT | 398 | 19% | 42% | 37% | 12% | 15% | – | 11% | – | 3% | – | 8% | 3% | 6 | 82% | P=0.16 |
| B. Cetux-CRT | 394 | 8% | 46% | 32% | 0% | 1% | – | 0% | – | 0% | – | 12% | 0% | 6 | 77% | ||
| Mehanna et al. (21) | A. HDC-CRT | 162 | – | – | – | 12% (hematologic) | 12% | 7% | 6% | 4% | 2% | – | – | P=0.49 | |||
| B. Cetux-CRT | 165 | – | – | – | 1% (hematologic) | 13% | 0% | 10% | 30% | 2% | – | – | |||||
| Shapiro et al. (22) | A. HDC-CRT | No data on acute toxicity. Late toxicity was highest with 5FU/carboplatin (25%) vs. cisplatin (8%) vs. cetuximab (7.7%). | B>A, P=0.05; B>C, P=0.02 | ||||||||||||||
| B. Carbo-CRT | |||||||||||||||||
| C. Cetux-CRT | |||||||||||||||||
| Denis et al. (23) | A. RT alone | No data on acute toxicity. Late toxicity no significant difference between arms | |||||||||||||||
| B. Carbo-CRT | |||||||||||||||||
| Tao et al., Abstract only (24) | A. HDC-CRT | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| B. Cetux/Ave-RT | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
Cis, cisplatin; CRT, chemoradiation; Pts, patients; N/V, nausea or vomiting; Tbcp, thrombocytopenia; Neuro, neurological; Diff, difference; RT, radiotherapy; Cetux, cetuximab; HDC, high dose cisplatin; Carbo, carboplatin; Cetux/Ave, cetuximab or avelumab; 5FU, 5-fluorouracil.